Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Response to Anti-HER2 Therapies

NCT04517838 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04517838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04517838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Response to Anti-HER2 Therapies
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
July 31, 2020
Completion date
July 27, 2028
Enrollment
230 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, breast adenocarcinoma, her2-positive breast carcinoma